Hahn: FDA Weighs Whether Some COVID-19 Policies Could Be Extended

FDA chief Stephen Hahn has asked agency officials to look into whether some of the more flexible and novel approaches FDA has taken to respond to COVID-19, including allowing remote clinical trial visits, using real-world evidence to make certain regulatory decisions and streamlining lab test approvals, could be applied more broadly and on a more permanent basis. “I think the entire FDA team has now seen firsthand that we need to take a critical look at some of our processes...